Answers are grounded in this paper and cite their sources.
Identifies radiomic biomarkers to guide therapy selection in bladder cancer, highlighting potential for improved outcomes.
Magnetic resonance imaging radiomics shows promise in guiding the selection of patients most likely to benefit from the use of immune checkpoint inhibitor therapy in patients with very‐high‐risk, nonmuscle‐invasive bladder cancer. This work arrives at a moment of rapid expansion in bladder‐sparing therapeutics, even as biomarker‐guided patient selection remains conspicuously absent across the field.
No takes yet. Share an insight, caveat, or question.
Walker et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: